Clik here to view.
Ampoules packaging market forecast to 2033
A report by The Brainy Insights has predicted that the ampoules packaging market will value $9.83 billion by 2033. This is expected to be largely driven by increasing demand for this packaging type. A...
View ArticleClik here to view.
Lignin-based drug delivery system may improve chemotherapeutics
Researchers have defined the conditions to formulate novel polyelectrolyte complexes (PECs) based on a sustainable hemicellulose-rich lignosulphonate. Their findings suggest potential applications in...
View ArticleClik here to view.
Harnessing small molecules to treat chronic inflammatory diseases
According to Biotech Abivax SA, obefazimod is the only small molecule drug candidate in clinical development with a mechanism of action that induces production of microRNA, or miRNA (miR-124), a potent...
View ArticleClik here to view.
Two novel biosimilars approved in EU and US
The European Commission (EC) has granted the first approval for an omalizumab biosimilar in Europe. Omlyclo® (CT-P39) is authorised as a biosimilar referencing Xolair®. CT-P39 is indicated for allergic...
View ArticleClik here to view.
LBP-immunotherapy could benefit oncology patients
The safety and tolerability of rationally-designed live bacterial product (LBP) BMC128 combined with nivolumab has shown initial positive trends in non-small cell lung cancer (NSCLC), melanoma, or...
View ArticleClik here to view.
Pioneering AAV gene therapy for Krabbe disease
What makes AAV gene therapies promising when compared to other gene therapies? A distinguishing factor of AAVs compared to other delivery methods for gene therapies is low incidence of toxicity in...
View ArticleClik here to view.
Ophthalmology acquisition to advance tri-specific antibody
Merck (known as MSD outside of the US and Canada) plans to acquire Eyebiotech Limited, with the aim to advance development of novel treatments for vision disorders. The deal has a potential value of $3...
View ArticleClik here to view.
Innovative nanocage promises sustainable cancer drug delivery
A novel drug delivery method combining proline and metal such as palladium, could enable chemotherapy drugs to be transported in the body via nano-sized cages. Practically, this could enable delivering...
View ArticleClik here to view.
Oligonucleotide ALS therapy approved in EU
The first treatment approved in the EU to target a genetic cause of amyotrophic lateral sclerosis (ALS), has been authorised by the European Commission (EC). QALSODY ® (tofersen) is indicated for...
View ArticleClik here to view.
Sustainable RP-HPLC method for simultaneous determination of hypertension drugs
Researchers have demonstrated a reverse phase-high performance liquid chromatography (RP-HPLC) method for the simultaneous determination of Amlodipine and Irbesartan using analytical quality by design...
View ArticleClik here to view.
AstraZeneca immunotherapy could boost lung cancer survival
IMFINZI® (durvalumab) has demonstrated statistically significant and clinically meaningful improvements in survival rates in lung cancer, new Phase III trial results show. This is based on interim...
View ArticleClik here to view.
Technology innovation aiding process spectroscopy market growth
A report by Spherical Insights has predicted that the process spectroscopy market will value $35.8 billion by 2033. Process spectroscopy is becoming more connected to automation and digitalisation...
View ArticleClik here to view.
Eli Lilly selects new EVP of Global Quality
Eli Lilly and Company has announced its new Executive Vice President of Global Quality. This news follows a statement by the firm at the start of this year declaring the retirement of its long-serving...
View ArticleClik here to view.
Biologic demonstrates durable tumour regression in rectal cancer
New clinical data from a Phase II trial for rectal cancer has revealed a 100 percent clinical complete response rate following first-line therapy with Jemperli (dostarlimab-gxly). These findings from...
View ArticleClik here to view.
Innovating small molecule injectables: market forecast to 2033
A report by the Business Research Company predicts that the small molecule injectable drugs market will value $355.14 billion in 2028. As such, the compound annual growth rate (CAGR) is expected to be...
View ArticleClik here to view.
WuXi facility boosts bioprocessing capacity with new bioreactors
WuXi Biologics has successfully installed three new sets of 5,000L single-use bioreactors at its MFG20 drug substance manufacturing facility in Hangzhou, China. Fitted in the facility’s second drug...
View ArticleClik here to view.
Advancing targeted treatments for multiple myeloma
In recent years, several key treatments for multiple myeloma have shown potential to address challenges in the field, such as improving key endpoints like patient survival and response rates and...
View ArticleClik here to view.
Combination therapy may hold potential for severe viral hepatitis
Final Phase IIb data has confirmed the potential of bulevirtide 10mg in combination with pegylated interferon alfa-2a (PegIFN) as a finite therapy for adults with chronic hepatitis delta virus (HDV),...
View ArticleClik here to view.
First-in-class telomerase inhibitor approved for blood cancer
The first telomerase inhibitor has been approved by the US Food and Drug Administration (FDA). RYTELO (imetelstat) is authorised for adults with low- to intermediate-1 risk myelodysplastic syndromes...
View ArticleClik here to view.
GLP-1 treatment displays best-in-class potential for MASH
New sub-analysis data from a Phase II clinical trial show that after 48 weeks of survodutide treatment, 83.0 percent of adults with liver fibrosis achieved a statistically significant improvement of...
View Article